Hing C Wong has bought HCWB on 8 days since Aug 2021

Dr. Hing C. Wong is a biotechnology executive and the Founder and Chief Executive Officer of HCW Biologics Inc. (NASDAQ: HCWB), a clinical‑stage biopharmaceutical company focused on developing novel immunotherapies that target chronic, low‑grade inflammation underlying age‑related diseases.( He has served as CEO and a member of the board of HCW Biologics since founding the company in April 2018, and also serves as a corporate officer, including secretary.( Under his leadership, HCW Biologics has advanced a pipeline of immunotherapeutic candidates aimed at extending health span by modulating the immune system.(

Dr. Wong has more than 35 years of experience in the life sciences industry, spanning early‑stage startups and established global companies.( Before HCW Biologics, he founded and served as CEO of Altor BioScience Corporation from 2002 until its acquisition by NantCell, Inc. (later ImmunityBio, Inc.) in 2017, and founded and led Sunol Molecular Corporation from 1996 to 2002.( Following Altor’s acquisition, he was CEO of NantCell until March 2018.( Earlier in his career, he held senior roles as Director, Biology Skills Center at Baxter Healthcare and Director of Microbial Genetics at Cetus Corporation.( Dr. Wong received his Ph.D. in Microbiology and Immunology from the University of Massachusetts Amherst and completed postdoctoral training at the University of Washington; he is the major or lead author of over 100 peer‑reviewed research articles and an inventor on numerous worldwide patents.( In recognition of his entrepreneurial impact, he was named the 2021 Weaver H. Gaines Entrepreneur of the Year by BioFlorida.(

Written by Perplexity from public sources.